Causaly, the leading company in artificial intelligence for life sciences, has entered a strategic collaboration with Microsoft during the Microsoft Build 2026 event to merge enterprise-grade scientific computation and interpretation into one cohesive workflow for biopharma R&D. This initiative aims to address a scenario wherein large amounts of computational signals are produced by research teams yet hindered by manual synthesis of data and disparate program histories. The collaborative solution merges Microsoft Discovery’s enterprise-scale analytics, prediction, and simulation capabilities with Causaly’s knowledge-graph reasoning and agentic AI platform, which searches, visualizes, and interprets extensive internal and external biomedical sources. Designed specifically for critical, time-sensitive R&D functions, the platform targets bottlenecks in target identification, prioritization, biomarker strategy, in silico prediction validation, and mechanism of action (MoA) plausibility.
Also Read: OpenAI Pioneers “Defensive Acceleration” in Biosecurity with Rosalind Biodefense Initiative
Emphasizing the core challenge facing the industry, Yiannis Kiachopoulos, co-founder and CEO of Causaly, stated, “Drug discovery does not suffer from a lack of data. It suffers from a lack of trustworthy interpretation,” adding that “Microsoft Discovery runs scientific computation over enterprise data, and Causaly brings the prior knowledge, mechanistic reasoning, and provenance that turns those signals into decisions. This is how serious R&D gets done from here: governed, grounded, and accountable to scientific judgement.” Supporting this vision, Aseem Datar, corporate vice president, product innovation, Microsoft Discovery & Quantum, noted, “Microsoft Discovery is designed to accelerate science and unlock insights hidden in an organization’s internal scientific data,” but explained that “insights are only as valuable as the decisions they support. Causaly provides the prior-knowledge intelligence to determine whether these insights are biologically meaningful and consistent with an organization’s existing use cases and institutional knowledge. Microsoft Discovery can then support validation through advanced computing and integrations with laboratory automation systems. Together, we give biopharma R&D teams an end-to-end scientific workflow, from raw data to cited decision.” Ultimately, this partnership ensures biopharma customers experience faster iterations, higher-confidence go/no-go decisions, and the absolute provenance needed for strict scientific review and regulatory oversight.
